This year 2020 marked by the Covid-19 pandemic is delicate for all categories of industry and business, but it is no exaggeration to say that the medical and health sector are particularly put to the test, in several areas: research and manufacture of treatments, vaccines, their financing, screening, prevention, etc.

Many negative points and shortcomings could appear in terms of anticipation, reactions, and even at the strictly medical level. However, the healthcare industry must look to the future in order to try to fill its gaps and possibly catch up on its digital transformation .

What the Covid-19 Crisis Reveals About Our Health Industry

Thus, everyone notes that the healthcare professions have undergone few transformations and developments over the past ten years. This is particularly striking if we look at what has happened in other service and production sectors such as retail, the automotive industry, or IT.

This Covid-19 health crisis can be an opportunity to turn the world of medicine and the pharmaceutical industry upside down by Cambodia Email Address working on concrete avenues such as artificial intelligence, the digital transformation of the sector, the creation of new business models, etc.

Cambodia Email Address

A remarkable example which perfectly illustrates our point is the appearance of “tele-medicine”. Looked down on by doctors and considered inconceivable a few months ago, this solution came naturally during the pandemic and the numbers of online consultation requests exploded on platforms such as Doctolib. The leader in e-health in France has thus recorded an impressive increase in the number of doctors and patients adopting this new way of considering the medical relationship.

We have also seen the leading companies of Heath Tech mobilize, in particular to ensure the treatment of patients with serious diseases, such as cancer, and often forced to stay at home because of the pandemic and the containment measures.

In addition, some pharmaceutical companies are still currently focusing their energy on research and development of treatments and a vaccine. One of the biggest challenges facing pharmaceutical manufacturers, highlighted by the Covid-19 crisis, is the continuity of the production and supply of drugs in times of emergency, but also the ability to diversify or increase their production depending on the health status at a given time.

The Track of Artificial Intelligence

Artificial intelligence is certainly the future of medicine, and it could be a fantastic ally for doctors to help them with many tasks, such as checking for symptomatic signs of a virus. Unquestionably, AI constitutes this very effective instrument which will come to support humans in order to increase diagnostic and medical analysis capacities. For example, AI offers the possibility of detecting subgroups of patients or patients that it is unrealistic to be able to detect in clinical trials at the present time, because certain data such as biomarkers are beyond the reach of researchers. conventional computer systems.

Artificial intelligence offers substantial progress in clinical trials thanks to better patient stratification, more efficient quantification of lesions on scanners, and optimization of biomarker combinations.

All these elements put together will improve research and therapeutic development.

In the area of ​​data analysis after drugs are brought to market, AI can greatly help medical and pharmaceutical institutions to better perceive and understand the effects of treatments on patients.

The Question of Access to Medical Data

For artificial intelligence to be able to express its full potential, it needs to have recourse to “data”. Interestingly, the number of scientific publications has skyrocketed in recent weeks around the world, with every country keen to find a cure, or even a vaccine, first. This makes available immeasurable amounts of data, which only AI could have the capacity and the faculty to process in a reasonable amount of time. There remains the problem of knowing how to make these huge amounts of data available to researchers specializing in AI, and especially to whom to entrust them.

Because the issue of confidentiality remains one of the main obstacles to the feasibility of such a project. That said, some companies and start-ups operating in cutting-edge sectors at the medical level succeed in setting up programs, such as Okwin, a French start-up created by a former head of clinic, Thomas Clozel. Thus, Okwin managed to design a European open source data sharing consortium called COAI and to develop a means of accessing data within medical institutions without extracting them, and therefore, without violating their confidentiality.

Leave a Reply

Your email address will not be published.